Last reviewed · How we verify

Salmeterol and Salmeterol / Fluticasone — Competitive Intelligence Brief

Salmeterol and Salmeterol / Fluticasone (Salmeterol and Salmeterol / Fluticasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / Inhaled corticosteroid combination. Area: Respiratory / Pulmonology.

marketed Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor / Glucocorticoid receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol and Salmeterol / Fluticasone (Salmeterol and Salmeterol / Fluticasone) — University of Rostock. Salmeterol is a long-acting beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation, while fluticasone is a corticosteroid that reduces airway inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Salmeterol and Salmeterol / Fluticasone TARGET Salmeterol and Salmeterol / Fluticasone University of Rostock marketed Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor / Glucocorticoid receptor
Seretide 500 Accuhaler Seretide 500 Accuhaler University of Southampton marketed Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol/ fluticasone propionate Salmeterol/ fluticasone propionate GlaxoSmithKline marketed Long-acting beta-2 agonist / inhaled corticosteroid combination Beta-2 adrenergic receptor; glucocorticoid receptor
Salmeterol xinafoate/fluticasone propionate combination Salmeterol xinafoate/fluticasone propionate combination GlaxoSmithKline marketed Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor (salmeterol); Glucocorticoid receptor (fluticasone propionate)
Salmeterol and Fluticasone Salmeterol and Fluticasone GlaxoSmithKline marketed Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor (salmeterol); glucocorticoid receptor (fluticasone)
Formoterol/Fluticasone Formoterol/Fluticasone Eurofarma Laboratorios S.A. phase 3 Long-acting beta-2 agonist / Inhaled corticosteroid combination Beta-2 adrenergic receptor; Glucocorticoid receptor
Seretide® Accuhaler® 250/50 µg/actuation Seretide® Accuhaler® 250/50 µg/actuation Chiesi Farmaceutici S.p.A. phase 3 Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) Beta-2 adrenergic receptor; Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / Inhaled corticosteroid combination class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. Eurofarma Laboratorios S.A. · 1 drug in this class
  3. University of Rostock · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol and Salmeterol / Fluticasone — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-and-salmeterol-fluticasone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: